



Living with chronic cough: experiences, burden and management in interstitial lung disease – a mixed methods study

Copyright ©The authors 2024

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org

Received: 3 April 2024
Accepted: 23 Aug 2024

To the Editor:

Chronic cough (CC), defined as cough lasting for 8 weeks or more, is a prevalent and complex issue in interstitial lung disease (ILD) [1, 2]. Current research relies on quantitative diagnostic tests and patient-reported outcome measures (PROMs) to describe the impact of CC [3], while recent qualitative studies reveal its profound effect on quality of life [4]. These individual approaches, however, are insufficient to grasp the multifaceted nature of CC in ILD.

Combining qualitative and quantitative methodologies within validated frameworks allows for comprehensive understanding of CC in ILD. An integrated approach will facilitate developments of patient-centred treatment strategies, to address the complexities of CC and patient outcomes. Therefore, a mixed methods study is essential. To address this gap, we combined semi-structured interviews with validated PROMs to explore the characteristics, impact and management strategies of CC in people with ILD.

This is a secondary analysis of a study exploring the feasibility of a non-pharmacological cough therapy (Clinicaltrials.gov: NCT04767074). Participants were recruited from pulmonary rehabilitation programmes at West Park Healthcare Center and St. Joseph's Healthcare Hamilton between February 2021 and December 2023 (local ethics boards approved the study, ref. 20-005-WP and HiREB #13017). Participants with diagnosed ILD and cough lasting ≥ 8 weeks were eligible. Exclusion criteria included: acute respiratory exacerbation, infection, or medication changes within the past month; use of angiotensin-converting enzyme inhibitors; existing medical conditions preventing exercise training; moderate or large amounts of sputum production (>2 tablespoons), as cough suppression therapy may be contraindicated in these cases [5]. The exclusion criteria and non-pharmacological cough therapy are detailed elsewhere [6].

Out of 29 interested individuals, 14 were ineligible, and four dropped out before the study began, leaving 11 participants included. After receiving consent, participants' sociodemographic and clinical characteristics were extracted from medical charts or self-reported. Participants completed the Cough Hypersensitivity Questionnaire (CHQ) [7] and the Leicester Cough Questionnaire (LCQ) [8]. Semi-structured interviews were conducted *via* Zoom by two researchers (A. Oliveira and A. Newman) not involved in the care of the participants. The interviews followed a guide with open-ended questions about participants' cough and management strategies, informed by previous literature and frameworks and the research team's expertise [9, 10].

Transcription analyses were completed by two researchers (S. Quach and A. Oliveira) using a hybrid thematic analysis combining inductive and deductive coding and theme development [9–11]. Thematic mapping was employed at each stage to track the development and evolution of themes and subthemes throughout the analysis. CHQ and LCQ scores were matched to the most appropriate subthemes to quantitatively characterise participants' experiences.

11 (four females, 37%) participants from West Park Healthcare Center (n=3, 27%) and St. Joseph's Healthcare Hamilton (n=8, 73%) enrolled, with a median (interquartile range) age of 67 (59–68) years.



Shareable abstract (@ERSpublications)

People living with interstitial lung disease and chronic cough have unique experiences in their cough characteristics, triggers, management strategies and overall impact on quality of life <https://bit.ly/4e8vNZl>

Cite this article as: Quach S, Newman A, LeBouedec M, *et al.* Living with chronic cough: experiences, burden and management in interstitial lung disease – a mixed methods study. *ERJ Open Res* 2024; 11: 00641-2024 [DOI: 10.1183/23120541.00641-2024].



Participants reported up to 5 years of CC following their diagnosis. Three (27%) never smoked, and the remainder ($n=8$, 73%) had a smoking history ranging from 2 to 27 years. Three participants (27%) used oxygen therapy ($1.5\text{--}4\text{ L}\cdot\text{min}^{-1}$) at rest and seven (64%) required oxygen therapy during exertion ($2\text{--}15\text{ L}\cdot\text{min}^{-1}$).

Three main themes were identified from the interviews (characteristics, consequences, coping and self-management) with a total of 17 subthemes. Participants' CHQ and LCQ scores were matched to distinguishing quotes from interviews (figure 1).

During the interviews, participants reported their CC to have sudden, random and multiple triggers, including emotions, time of day, season, talking, morning phlegm and oxygen therapy. Hypersensitivity to various triggers was reflected in participants' moderately high CHQ scores (15 (15–18) out of 23). When triggered, cough frequency, fit and duration varied, occurring 2–7 times consecutively and lasting from seconds to minutes or hours. Coughs were sometimes strong and intense, more prominent at certain times of the day and activity dependent, leading to participants' perception of always coughing.

CC consequences varied over time and by day. Participant-reported symptoms from interviews included tachycardia, dyspnoea, voice changes, throat soreness, chest tightness, chest pain and variable sputum production. 10 participants noted their coughs exacerbated dyspnoea and fatigue, impacting their physical capacity (LCQ physical 4.25 (4–5) out of 7). Their CC also caused embarrassment, self-consciousness and anxiety, affecting their psychological well-being (LCQ psychological 4.43 (2.89–4.86) out of 7) and preventing them from engaging in social events (LCQ social 3.75 (3.75–5) out of 7). Overall, participants felt their quality of life was significantly impacted by their cough as reflected in the LCQ total score (12.18 (10.43–14.86) out of 21).

Participants used pharmacological and non-pharmacological methods to manage CC. Pharmacological treatments included over-the-counter and prescribed medications for their underlying diseases, such as antifibrotics, proton pump inhibitors, antitussives and antibiotics. Non-pharmacological techniques included behaviour changes, rehabilitation, coping approaches and lifestyle modifications. Pulmonary rehabilitation helped participants optimise their lifestyle routines by educating them on airway clearance, breathing and energy conservation techniques to help control their cough. Participants were aware of their coughing patterns, with many recognising signs and sensations before they started coughing, allowing them to suppress or induce coughs to address the underlying trigger. The effectiveness of these techniques varied, with participants often trying multiple strategies simultaneously, without professional help. Participants reported their healthcare providers usually described their coughs as incurable and part of the disease. However, they expressed the need for more information to guide and support them in developing self-management skills.

By matching qualitative and quantitative data, our study highlights unique characteristics of CC in people with ILD not previously reported. Our participants identified oxygen therapy as a cough trigger, contributing to the existing body of knowledge [4]. The drying effect of long-term oxygen therapy, frequently used in individuals with advanced ILD, can cause irritation, inflammation and desiccation of mucous membranes, triggering a cough reflex [12]. This trigger is not considered in commonly used questionnaires like the CHQ.

Reported treatment ineffectiveness may stem from participants' use of self-management techniques without professional guidance. Their cough management needs are often unrecognised by clinicians, prompting them to seek their own information and strategies [13, 14]. However, cough management techniques require professional guidance to ensure appropriateness and proper implementation as techniques should be patient-tailored. The variability in cough characteristics further complicates management, highlighting the need for personalised self-management resources and support [15].

CC significantly burdens people with ILD [2], and our participants reported poorer quality of life compared to those with refractory CC (persisting cough despite targeted treatments) [9, 10], reflected in their lower LCQ scores [9, 16]. This may be due to their CC's unpredictability, variable triggers and ineffective management. We reported quantitative measures (CHQ, LCQ) with matched subthemes to describe our participants' unique experiences objectively. However, these cough-related PROMs were insufficient at providing comprehensive impressions of triggers and management experiences of individuals' ILD and CC. Therefore, validated cough-related PROMs for quality of life, symptoms, psychological well-being, functional status, knowledge and coping mechanisms in people with ILD are needed.




FIGURE 1 Three main themes and 17 subthemes were identified to describe participants' chronic cough. For each subtheme, a participant quote is provided to illustrate their experience. Where appropriate, the Leicester Cough Questionnaire (LCQ) and Cough Hypersensitivity Questionnaire (CHQ) subdomain and total scores were paired with subthemes.

Limitations to our study include a small sample size and participants recruited exclusively from pulmonary rehabilitation programmes, which may introduce bias, as those enrolled in pulmonary rehabilitation may be inherently interested in managing their CC. However, we sampled participants from two regions to reflect diverse ILD subpopulations.

In conclusion, the unpredictability of CC in ILD impacts social interactions, limiting participants' time with others, contributing to poor quality of life. Participants often felt frustrated and embarrassed by their cough, needing better management strategies as current ones are ineffective. Future work must address patients' needs for better support from clinicians, exploring additional management strategies and evaluating their effectiveness.

Shirley Quach ^{1,2}, Anatasia Newman^{1,2}, Matisse LeBouedec³, Renata Mancopes⁴, Diana Hatzoglou⁵, Natya Raghavan⁶, Dina Brooks^{1,2,7} and Ana Oliveira ^{1,8,9}

¹School of Rehabilitation Science, McMaster University, Hamilton, Canada. ²Respiratory Research, West Park Healthcare Center, Toronto, Canada. ³Queen's University, Kingston, Canada. ⁴KITE Research Institute, University Health Network, Toronto, Canada. ⁵Respiratory Rehabilitation Day Program, St Joseph's Healthcare, Hamilton, Canada. ⁶Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Canada. ⁷Rehabilitation Science Institute, University of Toronto, Toronto, Canada. ⁸Respiratory Research and Rehabilitation Laboratory (Lab3R), School of Health Sciences (ESSUA), University of Aveiro, Aveiro, Portugal. ⁹iBiMED – Institute of Biomedicine, Department of Medical Sciences, University of Aveiro, Aveiro, Portugal.

Corresponding author: Ana Oliveria (alao@ua.pt)

Provenance: Submitted article, peer reviewed.

Ethics statement: Participants were recruited and asked about their experiences with interstitial lung disease and chronic cough. Ethical approval was obtained from both locations.

Conflict of interest: A. Oliveira is an associate editor of this journal. The other authors have nothing to disclose.

Support statement: This study was supported by the Canadian Lung Association. Funding information for this article has been deposited with the Crossref Funder Registry.

References

- 1 Assayag D, Camp PG, Fisher J, et al. Comprehensive management of fibrotic interstitial lung diseases: a Canadian Thoracic Society position statement. *Can J Respir Crit Care Sleep Med* 2018; 2: 234–243.
- 2 Saita I, Mayhew AJ, Sohel N, et al. Prevalence, incidence and characteristics of chronic cough among adults from the Canadian Longitudinal Study on Aging. *ERJ Open Res* 2021; 7: 00160-2021.
- 3 Lee J, White E, Freiheit E, et al. Cough-specific quality of life predicts disease progression among patients with interstitial lung disease: data from the pulmonary fibrosis foundation patient registry. *CHEST* 2022; 162: 603–613.
- 4 Mann JMV, Holland AE, Goh NSL, et al. Understanding patient experience of chronic cough in interstitial lung disease. *ERJ Open Res* 2023; 9: 00039-2023.
- 5 Chamberlain Mitchell SA, Garrod R, Clark L, et al. Physiotherapy, and speech and language therapy intervention for patients with refractory chronic cough: a multicentre randomised control trial. *Thorax* 2017; 72: 129–136.
- 6 Dasouki S, Quach S, Mancopes R, et al. A non-pharmacological cough therapy for people with interstitial lung diseases: a case report. *Physiother Can* 2022; 75: 389–394.
- 7 La-Crette J, Lee KK, Chamberlain S, et al. P150 The development of a cough hypersensitivity questionnaire (CHQ). *Thorax*. 2012; 67: Suppl. 2, A127.
- 8 Birring SS, Prudon B, Carr AJ, et al. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). *Thorax* 2003; 58: 339–343.
- 9 Ueda N, Yakushiji A, Schelfhout J, et al. Impact of refractory and unexplained chronic cough on disease burden: a qualitative study. *BMC Pulm Med* 2022; 22: 372.
- 10 Kum E, Guyatt GH, Devji T, et al. Cough symptom severity in patients with refractory or unexplained chronic cough: a systematic survey and conceptual framework. *Eur Respir Rev* 2021; 30: 210104.

- 11 Fereday J, Muir-Cochrane E. Demonstrating rigor using thematic analysis: a hybrid approach of inductive and deductive coding and theme development. *Int J Qual Methods* 2006; 5: 80–92.
- 12 Mann J, Goh NSL, Holland AE, *et al.* Cough in idiopathic pulmonary fibrosis. *Front Rehabil Sci* 2021; 2: 751798.
- 13 Sanchez-Ramirez DC, Kosowan L, Singer A. Management of cough in patients with idiopathic interstitial lung diseases in primary care. *Chron Respir Dis* 2022; 19: 14799731221089319.
- 14 Lan NSH, Moore I, Lake F. Understanding cough in interstitial lung disease: a cross-sectional study on the adequacy of treatment. *Intern Med J* 2021; 51: 923–929.
- 15 Freitas Dos Santos S, Marques A, Rebelo P, *et al.* Effects of self-management interventions in people with interstitial lung disease. *Respiratory Care* 2024; 69: 114–127.
- 16 Puente-Maestu L, Dávila I, Quirce S, *et al.* Burden of refractory and unexplained chronic cough on patients' lives: a cohort study. *ERJ Open Res* 2023; 9: 00425-2023.